Gilead Sciencesvs.Vertex Pharmaceuticals
GILD vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 1.4× larger than Vertex Pharmaceuticals by market cap; year to date, Gilead Sciences leads (+19.6% vs +11.5%).
Side by side
| GILD | VRTX | |
|---|---|---|
| Market cap | $180B | $128B |
| Price | $147.10 | $503.25 |
| Today | +0.2% | −0.5% |
| Return YTD | +19.6% | +11.5% |
| Return 1Y | +25.7% | +23.2% |
| Since June 26, 2026 | +15.0% | +2.4% |
| P/E | — | 29.1 |
| P/S | 5.9 | 10.2 |
| P/B | 15.2 | 6.3 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →Vertex PharmaceuticalsVRTX
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Full VRTX profile →More GILD & VRTX comparisons
Other head-to-heads in the Biotech & innovation segment.